Breaking News Instant updates and real-time market news.

CLSD

Clearside Biomedical

$0.99

-0.0193 (-1.91%)

16:55
08/07/19
08/07
16:55
08/07/19
16:55

Clearside Biomedical reports Q2 EPS (15c), consensus (39c)

Cash and cash equivalents totaled $26.2 million as of June 30, 2019."We continue to make progress in leveraging Clearside's proprietary suprachoroidal space (SCS) injection platform," said George Lasezkay, Pharm.D., J.D., Clearside's Chief Executive Officer. "We recently announced an agreement with Aura Biosciences, which broadens the potential use of our SCS Microinjector(TM) technology into ocular oncology, where there is a significant unmet medical need. With ongoing exposure at medical conferences and in ophthalmic publications highlighting our targeted drug delivery approach, we are exploring various opportunities to prudently build our internal pipeline and we are also attracting significant interest from other companies to partner our technology like we did with Aura Biosciences."

  • 07

    Aug

  • 19

    Oct

CLSD Clearside Biomedical
$0.99

-0.0193 (-1.91%)

11/05/18
JPMS
11/05/18
DOWNGRADE
Target $8
JPMS
Underweight
JPMorgan double downgrades Clearside to Underweight on study failure
JPMorgan analyst Anupam Rama double downgraded Clearside Biomedical to Underweight from Overweight and lowered his price target for the shares to $8 from $16. The stock in early trading is down 56%, or $3.12, to $2.44. The analyst also removed Clearside from his firm's Analyst Focus List. The company this morning announced that the Phase 3 Sapphire results for Xipere plus Eylea in retinal vein occlusion did not meet the primary endpoint of third-line gainers versus Eylea alone, Rama tells investors in a research note. The results are "clearly disappointing," says Rama. The analyst sees no material value creation catalysts on the horizon and believes the overall negative sentiment on shares is unlikely to change until the company is closer to approval/commercialization.
11/05/18
COWN
11/05/18
DOWNGRADE
COWN
Market Perform
Clearside Biomedical downgraded earlier to Market Perform at Cowen
11/05/18
STFL
11/05/18
DOWNGRADE
Target $4
STFL
Hold
Clearside Biomedical downgraded to Hold from Buy at Stifel
Stifel analyst Annabel Samimy earlier downgraded Clearside Biomedical to Hold from Buy following the failure of the SAPPHIRE trial in RVO and subsequent discontinuation of the program. Clearside's value now depends primarily on the success of Xipere for the treatment of macular edema associated with non-infectious uveitis, said Samimy, who lowered her price target on the stock to $4 from $20. The SAPPHIRE failure also has implications for the future clinical design for DME, since "designing it as a superiority trial appears off the table now," Samimy believes.
11/06/18
NEED
11/06/18
NO CHANGE
Target $4
NEED
Buy
Clearside Biomedical price target lowered to $4 from $22 at Needham
Needham analyst Serge Belanger lowered his price target on Clearside Biomedical to $4 after its announcement yesterday that the Sapphire Phase 3 study evaluating Xipere in RVO patients did not meet its primary endpoint. The analyst also keeps his Buy rating, stating that while Clearside Biomedical is discontinuing the clinical development of its RVO program, it will remain focused on the Xipere opportunity in uveitis. Belanger adds that the valuation on the shares is now below cash levels and fails to capture the uveitis opportunity with potential peak sales of as high as $150M.

TODAY'S FREE FLY STORIES

NWS

News Corp

$14.48

0.02 (0.14%)

, NWSA

News Corp.

$14.17

0.07 (0.50%)

14:12
08/22/19
08/22
14:12
08/22/19
14:12
Periodicals
News Corp prepares news app to address concerns with Google, Facebook, WSJ says »

News Corp (NWSA) is…

NWS

News Corp

$14.48

0.02 (0.14%)

NWSA

News Corp.

$14.17

0.07 (0.50%)

GOOG

Alphabet

$1,191.47

0.68 (0.06%)

GOOGL

Alphabet Class A

$1,192.10

1.84 (0.15%)

FB

Facebook

$181.72

-1.84 (-1.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Sep

  • 23

    Sep

  • 24

    Sep

  • 27

    Oct

AMZN

Amazon.com

$1,815.98

-7.21 (-0.40%)

14:00
08/22/19
08/22
14:00
08/22/19
14:00
Periodicals
Amazon acquires 49% interest in India's Future Coupons, TechCrunch reports »

Amazon has acquired a 49%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

BTHE

Boston Therapeutics

$0.00

(0.00%)

13:56
08/22/19
08/22
13:56
08/22/19
13:56
Hot Stocks
Boston Therapeutics BTI320 Phase 2 study achieves full enrollment »

Boston Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$212.87

0.18 (0.08%)

, BABA

Alibaba

$171.93

-3.26 (-1.86%)

13:55
08/22/19
08/22
13:55
08/22/19
13:55
Periodicals
EU targets Apple, Google, others with EUR100B wealth fund plan, Politico says »

EU officials want to set…

AAPL

Apple

$212.87

0.18 (0.08%)

BABA

Alibaba

$171.93

-3.26 (-1.86%)

GOOG

Alphabet

$1,191.36

0.57 (0.05%)

GOOGL

Alphabet Class A

$1,192.66

2.4 (0.20%)

AMZN

Amazon.com

$1,815.25

-7.94 (-0.44%)

FB

Facebook

$182.08

-1.48 (-0.81%)

MSFT

Microsoft

$137.45

-1.32 (-0.95%)

BIDU

Baidu

$105.36

-2.55 (-2.36%)

TCEHY

Tencent

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Sep

  • 04

    Sep

  • 04

    Sep

  • 06

    Sep

  • 10

    Sep

  • 15

    Sep

  • 24

    Sep

  • 27

    Oct

SEDG

SolarEdge

$80.94

-6.93 (-7.89%)

13:55
08/22/19
08/22
13:55
08/22/19
13:55
Options
SolarEdge put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BNPQY

BNP Paribas

$0.00

(0.00%)

13:44
08/22/19
08/22
13:44
08/22/19
13:44
Periodicals
BNP Paribas cutting 500 jobs at securities services arm in France, Reuters says »

BNP Paribas will cut…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ETR

Entergy

$111.35

-0.32 (-0.29%)

13:39
08/22/19
08/22
13:39
08/22/19
13:39
Syndicate
Breaking Syndicate news story on Entergy »

Entergy files automatic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Nov

TELL

Tellurian

$9.04

0.75 (9.05%)

13:25
08/22/19
08/22
13:25
08/22/19
13:25
Options
Tellurian call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:25
08/22/19
08/22
13:25
08/22/19
13:25
General news
Treasury's $7 B 30-year TIPS reopening was well received »

Treasury's $7 B…

13:21
08/22/19
08/22
13:21
08/22/19
13:21
General news
30-Yr TIPS Auction Bid/Cover data reported »

30-Yr TIPS Auction…

13:21
08/22/19
08/22
13:21
08/22/19
13:21
General news
30-Yr TIPS Auction Total Amount data reported »

30-Yr TIPS Auction Total…

NTRA

Natera

$30.66

0.25 (0.82%)

13:18
08/22/19
08/22
13:18
08/22/19
13:18
Hot Stocks
Natera reports 'positive' local coverage determination issued by Palmetto MolDX »

Natera announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

13:17
08/22/19
08/22
13:17
08/22/19
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

13:16
08/22/19
08/22
13:16
08/22/19
13:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:15
08/22/19
08/22
13:15
08/22/19
13:15
General news
FX Action: USD-JPY »

FX Action: USD-JPY…

NTRA

Natera

$30.53

0.12 (0.39%)

13:13
08/22/19
08/22
13:13
08/22/19
13:13
Recommendations
Natera analyst commentary at Piper Jaffray »

Piper says Natera gets…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

13:10
08/22/19
08/22
13:10
08/22/19
13:10
General news
FX Action: USD-CAD »

FX Action: USD-CAD peaked…

AMGN

Amgen

$204.16

0.32 (0.16%)

13:06
08/22/19
08/22
13:06
08/22/19
13:06
Hot Stocks
Amgen granted orphan designation for multiple myeloma treatment »

Amgen was granted orphan…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

  • 16

    Sep

  • 19

    Sep

ZIOP

Ziopharm

$5.09

-0.06 (-1.17%)

13:05
08/22/19
08/22
13:05
08/22/19
13:05
Options
Ziopharm call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

  • 12

    Sep

SNY

Sanofi

$42.69

-0.48 (-1.11%)

13:04
08/22/19
08/22
13:04
08/22/19
13:04
Hot Stocks
Sanofi treatment of systemic sclerosis granted orphan designation »

Sanofi U.S. Service was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

  • 16

    Sep

  • 23

    Sep

  • 02

    Oct

WFC

Wells Fargo

$45.62

0.63 (1.40%)

13:03
08/22/19
08/22
13:03
08/22/19
13:03
Periodicals
Wells Fargo to pay $6.5M to Navajo Nation to settle account suit, Reuters says »

Wells Fargo intends to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Sep

  • 12

    Oct

  • 15

    Oct

  • 27

    Oct

ILMN

Illumina

$288.00

-2.5 (-0.86%)

13:02
08/22/19
08/22
13:02
08/22/19
13:02
Hot Stocks
Illumina granted orphan designation neuroblastoma management diagnostic »

Illumina…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Sep

OSTK

Overstock.com

$21.84

2.34 (12.00%)

12:49
08/22/19
08/22
12:49
08/22/19
12:49
Hot Stocks
Breaking Hot Stocks news story on Overstock.com »

Overstock.com trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OSTK

Overstock.com

$21.40

1.9 (9.74%)

12:45
08/22/19
08/22
12:45
08/22/19
12:45
Options
Overstock com call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMGN

Amgen

$203.13

-0.71 (-0.35%)

, ALXN

Alexion

$118.04

3.17 (2.76%)

12:43
08/22/19
08/22
12:43
08/22/19
12:43
Recommendations
Amgen, Alexion analyst commentary at Piper Jaffray »

Piper Jaffray says Amgen…

AMGN

Amgen

$203.13

-0.71 (-0.35%)

ALXN

Alexion

$118.04

3.17 (2.76%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

  • 16

    Sep

  • 19

    Sep

  • 02

    Oct

  • 19

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.